Abstract
In the field of erectile dysfunction (ED) therapy, few side-by-side comparative studies are carried out. The data from this clinical trial unequivocally show the superiority of intracorporal alprostadil over the intraurethral formulation.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
10.1 Key Trial References
10.1.1 Major Publication
Porst H. Transurethral alprostadil with MUSE™ (medicated urethral system for erection) vs intracavernous alprostadil — a comparative study in 103 patients with erectile dysfunction. Int J Impot Res 9:187–192, 1997.
10.1.2 Other Important Publications
Shabsigh R, Padma-Nathan H, et al. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative randomised, crossover, multicentre study. Urology 55(1):109–113, 2000.
Rights and permissions
Copyright information
© 2007 Springer-Verlag London Limited
About this chapter
Cite this chapter
(2007). Route of Administration Has a Considerable Impact on Clinical Profile: A Comparison of Intraurethral and Intracavernosal Alprostadil. In: Key Clinical Trials in Erectile Dysfunction. Springer, London. https://doi.org/10.1007/978-1-84628-428-1_10
Download citation
DOI: https://doi.org/10.1007/978-1-84628-428-1_10
Publisher Name: Springer, London
Print ISBN: 978-1-84628-427-4
Online ISBN: 978-1-84628-428-1
eBook Packages: MedicineMedicine (R0)